Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors

被引:27
作者
Deforche, K. [1 ]
Camacho, R.
Grossman, Z.
Silander, T.
Soares, M. A.
Moreau, Y.
Shafer, R. W.
Van Laethem, K.
Carvalho, A. P.
Wynhoven, B.
Cane, P.
Snoeck, J.
Clarke, J.
Sirivichayakul, S.
Ariyoshi, K.
Holguin, A.
Rudich, H.
Rodrigues, R.
Bouzas, M. B.
Cahn, P.
Brigido, L. F.
Soriano, V.
Sugiura, W.
Phanuphak, P.
Morris, L.
Weber, J.
Pillay, D.
Tanuri, A.
Harrigan, P. R.
Shapiro, J. M.
Katzenstein, D. A.
Kantor, R.
Vandamme, A.-M.
机构
[1] Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium
[2] Hosp Egas Moniz, Virol Lab, Lisbon, Portugal
[3] Minist Hlth, Chaim Sheba Med Ctr, Tel Aviv, Israel
[4] Helsinki Inst Informat Technol, Helsinki, Finland
[5] Univ Fed Rio de Janeiro, Dept Genet, BR-21941 Rio De Janeiro, Brazil
[6] Katholieke Univ Leuven, ESAT, Louvain, Belgium
[7] Brown Univ, Div Infect Dis, Providence, RI 02912 USA
[8] Katholieke Univ Leuven Hosp, AIDS Reference Lab, B-3000 Louvain, Belgium
[9] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada
[10] Wright Fleming Inst, Dept GUM & Communicable Dis, London, England
[11] Chulalongkorn Univ, Dept Med, Bangkok, Thailand
[12] Natl Inst Infect Dis, Dept Pathol, Tokyo, Japan
[13] Hosp Carlos III, Dept Infect Dis, Madrid, Spain
[14] Inst Adolfo Lutz Registro, Lab Retrovirol, Sao Paulo, Brazil
[15] Fdn Huesped, Buenos Aires, DF, Argentina
[16] Natl Inst Communicable Dis, AIDS Unit, Johannesburg, South Africa
[17] Hlth Protect Agcy, Antiviral Susceptibil Reference Unit, Birmingham, W Midlands, England
[18] Chaim Sheba Med Ctr, Natl Hemophilia Ctr, Tel Aviv, Israel
关键词
HIV; protease; nelfinavir; indinavir; saquinavir;
D O I
10.1016/j.meegid.2006.09.004
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Interpretation of Human Immunodeficiency Virus 1 (HIV-1) genotypic drug resistance is still a major challenge in the follow-up of antiviral therapy in infected patients. Because of the high degree of HIV-1 natural variation, complex interactions and stochastic behaviour of evolution, the role of resistance mutations is in many cases not well understood. Using Bayesian network learning of HIV-1 sequence data from diverse subtypes (A, B, C, F and G), we could determine the specific role of many resistance mutations against the protease inhibitors (PIs) nelfinavir (NFV), indinavir (IDV), and saquinavir (SQV). Such networks visualize relationships between treatment, selection of resistance mutations and presence of polymorphisms in a graphical way. The analysis identified 30N, 88S, and 90M for nelfinavir, 90M for saquinavir, and 82A/T and 46I/L for indinavir as most probable major resistance mutations. Moreover we found striking similarities for the role of many mutations against all of these drugs. For example, for all three inhibitors, we found that the novel mutation 891 was minor and associated with mutations at positions 90 and 71. Bayesian network learning provides an autonomous method to gain insight in the role of resistance mutations and the influence of HIV-1 natural variation. We successfully applied the method to three protease inhibitors. The analysis shows differences with current knowledge especially concerning resistance development in several non-B subtypes. (C) 2007 Published by Elsevier B.V..
引用
收藏
页码:382 / 390
页数:9
相关论文
共 23 条
  • [1] Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G
    Abecasis, AB
    Deforche, K
    Snoeck, J
    Bacheler, LT
    McKenna, P
    Carvalho, AP
    Gomes, P
    Camacho, RJ
    Vandamme, AM
    [J]. AIDS, 2005, 19 (16) : 1799 - 1806
  • [2] Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (Subtype E) infection differ from subtype B infection
    Ariyoshi, K
    Matsuda, M
    Miura, H
    Tateishi, S
    Yamada, T
    Sugiura, W
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (03) : 336 - 342
  • [3] BEERENWINKEL N, 2004, RECOMB, P36
  • [4] Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy
    Brindeiro, PA
    Brindeiro, RM
    Mortensen, C
    Hertogs, K
    De Vroey, V
    Rubini, NPM
    Sion, FS
    De Sá, CAM
    Machado, DM
    Succi, RCM
    Tanuri, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (12) : 4512 - 4519
  • [5] Low accumulation of L90M in protease from subtype FHIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism
    Calazans, A
    Brindeiro, R
    Brindeiro, P
    Verli, H
    Arruda, MB
    Gonzalez, LMF
    Guimaraes, JA
    Diaz, RS
    Antunes, OAC
    Tanuri, A
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (11) : 1961 - 1970
  • [6] An automated genotyping system for analysis of HIV-1 and other microbial sequences
    de Oliveira, T
    Deforche, K
    Cassol, S
    Salminen, M
    Paraskevis, D
    Seebregts, C
    Snoeck, J
    van Rensburg, EJ
    Wensing, AMJ
    van de Vijver, DA
    Boucher, CA
    Camacho, R
    Vandamme, AM
    [J]. BIOINFORMATICS, 2005, 21 (19) : 3797 - 3800
  • [7] DEFORCHE K, 2006, IN PRESS BIOINFORMAT
  • [8] Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients
    Frater, AJ
    Beardall, A
    Ariyoshi, K
    Churchill, D
    Galpin, S
    Clarke, JR
    Weber, JN
    McClure, MO
    [J]. AIDS, 2001, 15 (12) : 1493 - 1502
  • [9] Mutation D30N is not preferentially selected by human immunodeficiency virus type I subtype C in the development of resistance to nelfinavir
    Grossman, Z
    Paxinos, EE
    Averbuch, D
    Maayan, S
    Parkin, NT
    Engelhard, D
    Lorber, M
    Istomin, V
    Shaked, Y
    Mendelson, E
    Ram, D
    Petropoulos, CJ
    Schapiro, JM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) : 2159 - 2165
  • [10] Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B
    Grossman, Z
    Vardinon, N
    Chemtob, D
    Alkan, ML
    Bentwich, Z
    Burke, M
    Gottesman, G
    Istomin, V
    Levi, I
    Maayan, S
    Shahar, E
    Schapiro, JM
    [J]. AIDS, 2001, 15 (12) : 1453 - 1460